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ABSTRACT
Introduction Obesity is highly prevalent in older adults 
aged 65 years or older. Different lifestyle interventions 
(diet, exercise, self- management) are available but 
benefits and harms have not been fully quantified 
comparing all available health promotion interventions. 
Special consideration must be given to functional 
outcomes and possible adverse effects (loss of muscle and 
bone mass, hypoglycaemia) of weight loss interventions in 
this age group. The objective of this study is to synthesise 
the evidence regarding the effects of different types and 
modalities of lifestyle interventions, or their combinations, 
on physical function and obesity- related outcomes such as 
body composition in older adults with obesity.
Methods and analyses Six databases (Medline, Embase, 
Cochrane Central Register of Controlled Trials, Cumulated 
Index to Nursing and Allied Health Literature (CINAHL), 
Psychinfo and Web of Science) and two trial registries  
( Clinicaltrials. gov and the WHO International Clinical 
Trials Registry Platform) will be searched for randomised 
controlled trials of lifestyle interventions in older adults 
with obesity. Screening (title/abstract and full- text) and 
data extraction of references as well as assessment of 
risk of bias and rating of the certainty of evidence (Grading 
of Recommendations, Assessment, Development and 
Evaluation for network meta- analyses) will be performed 
by two reviewers independently. Frequentist random- 
effects network meta- analyses will be conducted to 
determine the pooled effects from each intervention.
Ethics and dissemination We will submit our findings 
to peer- reviewed journals and present at national and 
international conferences as well as in scientific medical 
societies. Patient- targeted dissemination will involve local 
and national advocate groups.
PROSPERO registration number CRD42019147286.
INTRODUCTION
Obesity is defined as an abnormal and exces-
sive accumulation of body fat,1 while on a 
population level, is defined using a body mass 
index (BMI) ≥30 kg/m2. Over the past four 
decades, the prevalence of obesity has been 
increasing worldwide across all age groups.2 
The rate of obesity in older adults, the fastest 
growing population segment,3 have now 
exceeded 40%, making this a public health 
concern.4 As BMI has poor sensitivity in 
older adults due to age- related changes in 
body composition and a reduction of body 
height,5 waist circumference and, more 
directly, objectively- measured fat mass can 
be considered in ascertaining obesity. In the 
USA, central obesity measured using waist 
circumference has been found in ~63% of 
community- dwelling adults aged ≥60 years.6 
The prevalence of obesity according to a high 
proportion of fat mass is 64% and 77% in 
German women and men ≥70 years, respec-
tively.7 8 Due to the higher mechanical load of 
a higher body weight, for a long time obesity 
has not been linked to a low proportion of 
muscle mass. However, in recent years, sarco-
penic obesity, a syndrome combining obesity 
with low muscle mass and strength or physical 
function, has gained considerable attention. 
Strengths and limitations of this study
 ► This will be the first network meta- analyses (NMA) 
on lifestyle interventions in older adults with obesity.
 ► Rather than focussing on weight loss, physical func-
tioning will be the primary interest due to its subjec-
tive and objective relevance for older people.
 ► Methods will be applied based on the standards of 
the updated version 6.0 of the Cochrane Handbook 
for Interventions (updated July 2019).
 ► Recommendations will be derived based on the re-
sults according to the Grading of Recommendations, 
Assessment, Development and Evaluation approach 
for NMA.
 ► Heterogeneity (clinical and statistical) will be evalu-
ated and discussed in detail.
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Sarcopenic obesity is a largely underdiagnosed condi-
tion in clinical practice, and prevalences of up to 94% in 
older adults depending on the operationalisation of this 
construct have been reported.9
In community- dwelling older adults, obesity and sarco-
penic obesity are associated with increased mortality10 11 
as well as with reduced quality of life (QoL).12 13 Contrary, 
several cohort studies have shown a lower risk for mortality 
in people with obesity and specific diseases such as type 2 
diabetes, coronary artery disease or serious illnesses,14–16 
which was described as ‘obesity paradox’. While research 
on this controversial phenomenon is still ongoing, several 
hypotheses are discussed, such as collider bias or effect 
modification.17–19 Obesity is a well- known risk factor for 
metabolic and cardiovascular diseases, pulmonary abnor-
malities and certain types of cancer in older age.20 Further-
more, obesity is associated with the onset of osteoarthritis 
in older adults,21 one of the most disabling medical condi-
tions, severely affecting one’s QoL.22 A meta- analysis of 
26 prospective studies in older adults revealed obesity 
as risk factor for functional decline23 which is of utmost 
importance for independent living.24 25 Older adults with 
sarcopenic obesity are considered a group at particular 
risk for functional limitations as they are suffering from 
two conditions determining functional disability simul-
taneously.26 27 Moreover, in older people obesity and 
sarcopenic obesity are associated with an increased risk of 
falls28–31 and nursing home admissions.32 Alley et al have 
predicted that given the increasing prevalence of obesity, 
a disabled older person with obesity may become the 
most common phenotype of frailty33—another syndrome 
in the geriatric population that is associated with decline 
in health and function34 35—posing a marked personal 
and societal burden. In 2015, a high BMI contributed to 
about 120 million disability- adjusted life years (DALYs) 
representing ~5% of DALYs from any causes among 
adults worldwide.2 A recent systematic review found that 
compared with healthy weight, the total annual health-
care costs are 30% (IQR: 20%–34%) higher in middle- 
aged and older people with obesity.36 An analysis of the 
World Obesity Foundation in 2017 has forecasted that 
costs of consequences of overweight and obesity will 
further increase in the future.37
Although other therapeutic options to treat obesity exist 
(eg, bariatric surgery), lifestyle strategies should always 
be first- line treatment.38–40 Lifestyle interventions mainly 
focus on diet, exercise, self- management or combined 
strategies that vary in treatment modality (eg, specific 
content), type of delivery (eg, level of supervision) and 
dose. Lifestyle interventions mainly focus on diet (eg, 
calorie restriction41), high- protein diet,42 exercise (eg, 
aerobic or resistance43), self- management interventions 
(eg, relapse prevention or self- monitoring techniques44) 
or combined strategies that vary in treatment modality 
(eg, specific content), type of delivery (eg, level of super-
vision, individual vs group sessions, in person vs tech-
nology) and dose (eg, duration, intensity). Findings from 
younger people cannot be generalised to older people 
due to higher levels of multimorbidity, frailty, sarcopenia 
and malnutrition risk.45 Moreover, harmful side effects 
of interventions aiming at weight loss have to be consid-
ered, such as reduced muscle mass46 and bone mineral 
density.47 Thus, in older people functional decline, func-
tional limitations as well as the risk of adverse events, 
such as falls and fractures, may be increased.48 Very low 
caloric diets may lead to an inadequate intake of nutri-
ents and consequently to the development of malnutri-
tion, another geriatric syndrome associated with adverse 
health events.49 In addition, perceived and actual barriers 
differ between younger and older adults in their impact 
on adopting lifestyle changes.50 Despite these issues, 
obesity treatment in older adults is still not sufficiently 
addressed in existing obesity guidelines.39 51 52
Several systematic reviews on obesity treatment in older 
adults have been published between 2006 and 201953–63 
including 126 publications of more than 60 distinct 
randomised controlled trials (RCTs). These systematic 
reviews, however, did not identify the same studies for 
inclusion due to different search strategies, databases, 
search dates as well as differing definitions of obesity and 
applying various age cut- offs. They generally agree that 
weight- loss interventions in older adults do not cause 
poor health outcomes (eg, higher risk for mortality for 
those randomised to the weight- loss group and signifi-
cantly reduce weight). Further, more limited evidence 
demonstrates improvements in measures of physical 
performance, such as gait speed. Combined interven-
tions (eg, including dietary and exercise components) 
are to be favoured to preserve muscle mass, bone mineral 
density and to improve physical performance. However, 
self- management strategies, which are important for 
long- term weight maintenance from studies in younger 
adults,64 have not been separately reported and discussed 
in existing reviews on the management of obesity in older 
adults. In addition, methodological issues prevent the 
drawing of firm conclusions, for example, recommen-
dations for obesity treatment. These include too specific 
searches in only one database, not covering the complete 
time period of databases and application of language 
restrictions. This must be considered insufficient as it 
likely missed relevant evidence.65 66 Further, a quality 
rating of the included RCTs was missing in the majority 
of these systematic reviews or when done, some used 
no standardised tools. The only published meta- analysis 
dates back to 2010,63 and there is no meta- analysis avail-
able for functional outcomes in older people with obesity. 
Considering, recently published intervention studies, for 
example, Ard et al67 and Beavers et al,68 it is likely that 
accumulated evidence enables quantitative syntheses.
These limitations of existing systematic reviews high-
light an evidence gap and justify the need for a thoroughly 
conducted high- quality systematic review according to the 
updated standards described by the Cochrane collabo-
ration for network meta- analysis.69 70 As older adults are 
particularly susceptible to negative effects of excess body 
mass on physical function due to the age- related decline 
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in muscle mass and strength20 and frequently report the 
priority of functional outcomes related to mobility and 
daily life tasks,71 these outcomes should be investigated 
comprehensively.
An important question remaining is which type of life-
style intervention or treatment modality offers optimal 
benefits in older adults with obesity. As there exist a large 
number of possible interventions, multiple pairwise meta- 
analyses are insufficient to provide an answer of high 
certainty. Therefore, we will conduct a comprehensive 
systematic review with network meta- analyses (NMA) of 
RCTs to synthesise the evidence regarding the beneficial 
and potentially harmful effects of different types and 
modalities of lifestyle interventions, or their combina-
tions, on physical function and obesity- related outcomes 
such as body composition in older adults with obesity and 
sarcopenic obesity.
METHODS AND ANALYSIS
Reporting
We report this protocol according to the Preferred 
Reporting Items for Systematic Review and Meta- Analyses 
statement for systematic review protocols (PRISMA- P, see 
online supplemental file 1),72 the additional guidance for 
NMA by Chaimani et al73 and the guidance for system-
atic reviews of older adults by Shenkin et al74 to ensure 
thorough reporting and implementation. The method-
ology is preregistered on the International Prospective 
Register of Systematic Reviews (registration number 
CRD42019147286).75
Eligibility criteria
We will select primary studies according to the criteria 
below.
Population
To focus this systematic review on older adults, we will 
include studies including adults with a minimum age of 60 
years and a mean of ≥65 years.76 Participants will be clas-
sified as obese if one of the following criteria is fulfilled: 
percentage of total body fat mass ≥35% and ≥25%77 or 
waist circumference of ≥88 cm and ≥102 cm for women 
and men,78 or BMI, applying the standard adult cut- off 
of ≥30 kg/m2 since there is no consensus on age- adjusted 
cut- offs.79 If proven valid, we will, however, consider 
different cut- off values for these criteria, for example, in 
Asian populations. For all three operationalisations, the 
methods of measurement applied by individual studies 
will be used. When studies report mixed samples of older 
adults with overweight and obesity, we will contact the 
authors to request the data for the subgroup with obesity. 
If the provision of data is not possible, the study will be 
excluded. No consensus definition of sarcopenic obesity 
exists and various operationalisations are in use.9 As 
such, the definition applied by the primary study will be 
used, and we shall acknowledge differences in potential 
subgroup or sensitivity analyses, if possible. Due to the 
high prevalence of multimorbidity in older people and 
existing obesity- related comorbidities, participants with 
common comorbidities of obesity (eg, diabetes, cardio-
vascular disease, metabolic syndrome, chronic kidney 
disease, osteoarthritis and geriatric syndromes (eg, frailty 
and sarcopenia)) will be included. We will only include 
studies comprising community- dwelling older adults, 
due to the predictive value of obesity for nursing home 
admissions.80 Studies focusing on animals, genetics or 
biochemistry will be excluded. References that have not 
been included after full- text screening will be listed in a 
table with the respective reason(s) for exclusion.
Interventions
We will include any type of lifestyle intervention, for 
example, diet, exercise, self- management, as well as all 
treatment modalities and their combinations with all 
types of deliveries and doses. For the dietary compo-
nent, interventions affecting energy balance, such as 
energy restriction, balanced (healthy) diet (eg, food 
pyramid), Mediterranean diet, high- protein diet, low- 
fat diet, moderate- carbohydrate diet, low- carbohydrate 
diet, low glycaemic index/glycaemic load diet, vegetarian 
diet, Dietary Approaches to Stop Hypertension (DASH), 
will be considered. Interventions providing only micro-
nutrient supplements (eg, vitamin D) as well as studies 
using only very low energy diets (<800 kcal/day) or total 
diet replacement will be excluded.81 Additionally, RCTs 
focussing on substances such as secondary plant prod-
ucts (eg, polyphenols), components of macronutrients 
(eg, fatty (docosahexaenoic acid) or amino acids (eg, 
leucin)) and fibres will also be excluded. The exercise 
component will be defined as any planned, structured 
and repetitive movement with the objective to improve 
or maintain physical fitness, for example, aerobic, resis-
tance, balance training, according to the definition of 
the American College of Sports Medicine.82 We will also 
consider physically supported methods, such as elec-
trical muscle stimulation and vibration training when 
combined with gross movements or done in an upright 
position. Finally, as recommended in obesity guidelines83 
we will include all self- management interventions that 
intend to support behaviour changes (such as motiva-
tional interviewing, social support, cognitive- therapeutic 
intervention).84 This is owed to the fact that many (older) 
people with chronic diseases (such as diabetes or obesity) 
have difficulties to control intended behavioural changes 
(such as improving eating behaviour, increasing physical 
activity and decreasing sedentary time).85 In addition, 
self- efficacy, self- regulation skills were found important 
mediators for successful weight change.86
Comparators
Since NMA will be conducted, all interventions will be 
compared with each other. Additionally, control groups, 
such as usual care or health counselling, will be consid-
ered as comparators.
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Outcomes
Only previously validated outcomes will be considered 
and need to be measured at least preintervention and 
postintervention.
Main outcome
The change in functional status with focus on physical 
function was shown to be important to health and adverse 
outcomes24 25 and patient- relevant71 and will therefore be 
our main outcome. This includes standard measures of 
strength, mobility and functional performance for inde-
pendence in daily living, including their modifications. 
Common measurements include but are not limited 
to one- leg stance (balance), gait speed (gait, mobility), 
6 min walk test (endurance), repeated chair stands 
(functional strength, lower extremity function), grip 
strength (strength, overall function), leg power as well 
as composite scores of functional tests such as the short- 
physical- performance battery25 or the physical perfor-
mance test.87 Patient- reported outcomes of functional 
status (eg, Late- Life Function and Disability Instrument) 
and digital measurements (eg, instrumented gait anal-
ysis)) will also be considered.
Other outcomes
To evaluate changes in weight and body composition, we 
will consider measures such as total body mass, fat mass 
(eg, total, central, peripheral), lean mass, muscle mass 
(eg, total, appendicular, lower extremity skeletal), bone 
mineral density (eg, hip, lumbar spine, whole body).
(Health- related) QoL will be summarised when reported 
by standardised instruments such as 36- item short form 
survey88 or EuroQol- 5D.89 If reported in primary studies, 
emotional status (eg, depressive symptoms, depression), 
social participation (eg, informal social relationships, 
community life) and satisfaction with intervention will 
also be captured.
Data on the occurrence of mortality, falls, fractures, 
hospital admission and nursing home placement as 
well as for other health- related event data (eg, hypogly-
caemia, hypotension), no matter if reported as outcome 
or adverse event, will also be considered for the current 
analysis.
Design of primary studies
We will include (quasi-) RCTs (parallel and crossover). 
Due to a lower level of initial fitness, prevalent health 
restrictions and the time needed to respond to treatment, 
we will include studies with intervention durations of ≥12 
weeks.50
We will not set any restrictions regarding language or 
time frame. We will involve colleagues who are fluent in 
the respective languages or use online translators (eg, 
https://www. deepl. com/ home).
Conference abstracts will be excluded.
Search strategy
Six electronic databases (Medline, Embase, Cochrane 
Central, Cumulated Index to Nursing and Allied Health 
Literature (CINAHL), PsychInfo and Web of Science) 
for published trials and two trial registries ( Clinicaltrials. 
gov, WHO International Clinical Trials Registry Platform) 
for unpublished or ongoing trials will be searched. We 
developed the search strategy for Medline (via Ovid) 
(see online supplemental file 2) using a search block for 
people aged ≥65 years and adapted a block for interven-
tions from a recently published Cochrane review evalu-
ating lifestyle interventions in paediatric patients with 
overweight and obesity, which was reviewed and revised by 
information specialists.90 For other databases, the search 
strategy will be adapted according to the database- specific 
requirements. Additionally, we will screen reference lists 
of published systematic reviews and eligible RCTs for 
potential consideration of further primary RCTs and will 
contact the advisory board which consists of clinical and 
scientific experts to enquire whether all relevant studies 
were identified.
Selection process
Identified references will be saved in Endnote and after 
excluding duplicates, references will be uploaded to 
Covidence (http://www. covidence. org). Two reviewers 
(GT, DS) will independently screen titles/abstracts and 
full texts for eligibility according to the criteria described 
above. The title/abstract screening will be piloted using 
the first 200 references and in case of too many devia-
tions (>10%), it will be revised. Disagreements will be 
solved by discussion or if no consensus can be reached 
by a third reviewer who will be asked based on his/her 
expertise (nutrition/general (EK), exercise (WK), self- 
management (NS- B)). If relevant information is lacking, 
we will contact the corresponding author/s twice at a 
weekly interval.
Data extraction
Two reviewers (GT, DS) will extract data of included 
references independently using a piloted data extraction 
table. In case of no consensus, a third reviewer (based on 
expertise) will solve disagreements. If relevant data are 
missing, we will contact the corresponding author/s twice 
at weekly intervals.
When extracting the data, we will consider the following 
information: study characteristics: for example, author, 
publication year, eligibility criteria, setting, study dura-
tion, sample size, follow- up time, conflict of interest; partic-
ipants’ characteristics: for example, age, sex, ethnicity, BMI, 
body composition (eg, fat mass, muscle mass, height/
weight adjusted indices), comorbidities (eg, diabetes, 
cardiovascular disease), geriatric syndromes (eg, sarco-
penia, frailty, cognitive impairment), functional status, 
lifestyle behaviour (eg, sedentary); intervention character-
istics: type and modality, type of delivery, dose (eg, dura-
tion, frequency, intensity), control arms, cointerventions, 
compliance and adherence, drop out, (serious) adverse 
events related to intervention; outcomes: baseline values 
and follow- up values of functional status, BMI, weight, 
body composition (lean mass, fat mass), QoL, emotional 
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status, social participation and any reported poor health 
outcome as reported by study authors.
Assessment of risk of bias
The risk of bias will be assessed after a pilot trial (n=3) 
by two reviewers (GT, DS; not blinded to authors and 
journal of primary studies) independently using the 
revised Cochrane risk of bias tool (RoB 2.0) for RCTs.91 92 
According to this, sources of bias will be identified by 
assessing: (1) the randomisation process, (2) deviations 
from intended interventions, (3) missing outcome data, 
(4) measurement of the outcome and (5) selection of the 
reported result. For each domain, available algorithms will 
be followed to answer the signalling questions (response 
options: yes, probably yes, probably no, no or no informa-
tion) and to judge the risk of bias as low, some concerns, 
or high. The overall risk of bias will also be rated as low 
(if low risk of bias in all domains), some concerns (at 
least one domain is rated as having some concerns but no 
domain is rated by a high risk of bias) or high (if at least 
one domain is judged with a high risk of bias or multiple 
domains are rated as having some concerns which might 
impact the confidence in a result). We will present results 
in a risk of bias summary graph.
Assessment of certainty of evidence
Grading of Recommendations, Assessment, Development 
and Evaluation approach for NMA will be used to assess 
the certainty of evidence.93–95 In addition to the risk of 
bias rating for every outcome, this includes the rating of 
direct and indirect evidence for inconsistency, indirect-
ness and dissemination bias. In case of high certainty and 
a similar contribution of direct and indirect evidence to 
the network estimate, the highest rating will be used but 
could be further downrated for incoherence and impreci-
sion. In case of insufficient evidence as well as moderate, 
low or very low certainty, the indirect estimate will be 
rated by the lowest of two direct comparisons included 
in first- order loops and could be further downrated for 
intransitivity. Dissemination bias will be investigated 
by searching for unpublished trials (see section search 
strategy). ‘Summary of findings’ tables adapted for NMA 
results will be presented, similar to the proposal by Yepes- 
Nuñez et al.96
Statistical analyses
Measures of treatment effect
Effect sizes for continuous outcomes (eg, weight loss, 
muscle strength) will be expressed as mean difference or 
standardised mean difference with 95% CI. For dichot-
omous outcomes (eg, negative health outcome such as 
death), effect sizes will be expressed as risk ratios with 
95% CI.97 In exceptional cases (ie, if a minor number 
of RCTs expressed as negative health outcome continu-
ously while the majority used dichotomous outcomes), 
the outcomes reported as continuous or categorical will 
be dichotomised.98 If the postintervention values with the 
corresponding SD are not available, the changed scores 
with the corresponding SD will be used.99
Data synthesis
We will conduct random effects model NMA based on a 
frequentist approach to derive pooled estimates for all 
outcomes.100 We will use the R package ‘netmeta’.101 In 
NMA, evidence from direct comparisons and indirect 
comparisons is averaged to calculate a network estimate. 
The key requirement for conducting NMA is that the 
transitivity assumption—to compare two interventions 
via an indirect route in the network—is ensured. We 
assume that for our planned analyses, all interventions 
are jointly randomisable73 102 and that all participants 
are likely to receive any kind of included interventions. 
Network graphs will be generated by function netgraph() 
of netmeta.101 103 We will assess global incoherence by 
decomposing the Q statistic into heterogeneity (within 
designs) and inconsistency (between designs) and visu-
alise this using a net- heat plot.104 In addition, we will 
report and assess inconsistency by calculating differences 
between direct and indirect effect estimates using descrip-
tive z- tests (function netsplit()) and report the distribution 
of direct and indirect evidence. The treatment modalities 
(eg, very low caloric diet, aerobic exercise, their combina-
tion or no intervention (eg, health counselling, healthy 
eating/ exercise advise)) will build the nodes of the 
network providing maximising similarity within and mini-
mising similarity between the nodes.93 To further identify 
important determinants of efficacy and safety, nodes will 
be further defined, for example, according to the dura-
tion, intensity, mode of delivery of interventions.105 Based 
on data availability, these nodes will be defined after data 
extraction. Additionally, we will analyse the components 
(eg, of combined interventions using an additive model 
for multicomponent interventions).106 Models of this 
type allow disentangling the effects of all single compo-
nents (eg, very low caloric diet (A), aerobic exercise (B), 
behavioural group counselling (C)) of a multicompo-
nent intervention arm consisting of at least two single 
components (eg, A+B, A+C, B+C or A+B+C). Since we do 
not believe that lifestyle interventions that are available 
for treatment of obesity may fulfil the additivity assump-
tion for component NMA (CNMA)—that is, the effect 
of a multicomponent intervention equals the sum of 
their components without any interactions—we will use 
the interaction CNMA model which is implemented in 
the function netcomb() of netmeta.101 106 In the case of 
disconnected networks, we will reconnect the networks if 
possible (ie, presence of at least one common component 
in the subnetworks). This feature of CNMA is also imple-
mented in netmeta (function discomb()).
A secondary data analysis will be conducted using inter-
vention types as network nodes (eg, diet, exercise, self- 
management). Results of NMA will be presented as forest 
plots. We will present league tables containing relative 
treatment effects for all direct comparisons (function 
netleague()) and a ranking of all treatments by P- scores.107
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Sensitivity and subgroup analyses
If possible, sensitivity analyses will be conducted by only 
including studies rated as low risk of bias. We will try to 
conduct subgroup analyses for type of obesity (sarcopenic 
obesity vs obesity), intervention duration (</>6 months), 
age (</>75 years), sex, BMI group (</>35 kg/m2) and 
comorbidities, such as diabetes or metabolic syndrome 
and frailty status. Patients’ characteristics for subgroup 
analysis were selected based on the assumption that life-
style interventions might work differently in people who 
differ in aspects like vulnerability, resilience and body 
composition.
Patient and public involvement
Before the start of this NMA, we have conducted and are 
currently analysing a qualitative study with semistructured 
interviews in older persons with obesity. The aim is to 
obtain further information on patients’ motives, barriers, 
experiences and perceptions regarding therapeutic lifestyle 
interventions and thus, potentially identify evidence gaps. 
The results will be published in a separate manuscript.
In addition, we discuss patient- relevant outcomes, 
existing obstacles that exacerbate the process of 
contacting this population of patients as well as potential 
dissemination strategies with representatives of German 
patient advocate groups.
ETHICS AND DISSEMINATION
For NMA, there is no direct data collection from human 
participants and hence, no ethical approval is necessary.
We will submit our research articles to peer- reviewed 
journals and will present our results at national and inter-
national conferences. Involved experts will disseminate 
the results in scientific and medical societies. We will 
further disseminate our project via partner universities’ 
websites and press releases. Patient- targeted dissemina-
tion will involve local and national advocate groups and 
offices for senior affairs. In addition, we will disseminate 
the results by distribution of materials in plain language.
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